BackEnliven Therapeutics Overview

Enliven Therapeutics Long Term Debt

Enliven Therapeutics's long-term debt is $910K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$913000.00

Peer trimmed avg / median

Loading

Enliven Therapeutics Long Term Debt History

Loading

Enliven Therapeutics vs. peers: Long Term Debt Comparison

Loading

Enliven Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Enliven Therapeutics (ELVN) FAQ

Enliven Therapeutics (ELVN) currently reports a long-term debt of $910K as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Enliven Therapeutics's long-term debt history and peer comparisons.

Enliven Therapeutics's long-term debt changed from $0 to $910K (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enliven Therapeutics reported $910K in long-term debt as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $910K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enliven Therapeutics, and consider following ELVN for alerts when major investors trade the stock.

Enliven Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $910K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELVN with unrelated industries.